Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma

Published:2016-07-09 Issue:1 Volume:23 Page:71-74
ISSN:1078-1552
Container-title:Journal of Oncology Pharmacy Practice
language:en
Short-container-title:J Oncol Pharm Pract

Author:

LaPorte Justin¹,Solh Melhem²,Ouanounou Serge¹

Affiliation:

1. Northside Hospital, Atlanta, GA, USA

2. Blood and Marrow Transplant Group of Georgia, Atlanta, GA, USA

Abstract

Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin’s Lymphoma patient after a dose of pembrolizumab.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1078155215620922

Reference9 articles.

1. Posterior Reversible Encephalopathy Syndrome in the Emergency Department: Case Series and Literature Review

2. The many faces of posterior reversible encephalopathy syndrome

3. Posterior reversible encephalopathy syndrome (PRES): Features on CT and MR imaging

4. Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

5. Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of posterior reversible encephalopathy syndrome (PRES) in an elderly patient with advanced classical Hodgkin Lymphoma during frontline treatment with brentuximab vedotin plus AVD;Leukemia & Lymphoma;2024-07-27

2. Evaluation and management of acute high-grade immunotherapy-related neurotoxicity;Heliyon;2023-03

3. Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity;SSRN Electronic Journal;2022

4. Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer;Cancer Treatment and Research Communications;2022

5. Encefalopatía posterior reversible asociada a combinación con pembrolizumab;Neurología;2021-09